Hydergine: Interaction with Neurotransmitter Systems in the Central Nervous System
Hydergine (co-dergocrine, ergoloid mesylates, dihydroergotoxine) is an ergot preparation shown to be of value in the treatment of senile mental impairment.
Inexperimental animals, Hydergine induces behaviors suggesting an influence on monoaminergic systems. Results from biochemical in vitro studies indicate that Hydergine has multiple effects and interacts directly with α-adrenoceptors, dopamine (DA), and serotonin (5-TH) receptor subtypes. In rat cortex slices, it blocks noradrenaline (NA)-induced cyclic adenosine monophosphate (cAMP) formation and facilitates evoked NA release. This indicates antagonistic effects at α 1 - and α 2 - adrenoceptors. Furthermore, Hydergine has mixed agonistic/antagonistic effects at postsynaptic DA receptors, stimulating adenylate cyclase and inhibiting action-potential-evoked acetylcholine release in the rat striatum. Also, at presynaptic DA receptors inhibiting evoked DA release in the rat striatum, Hydrergine has mixed agonistic/antagonistic effects.
Moreover, Hydergine was found to have mixed agonistic/antagonistic effects on 5-HT receptors involved in stimulating adenylate cyclase activity in homogenates of rat hippocampus. In slices of rat hippocampus, Hydergine enhanced electrically evoked acetylcholine release. Based on these findings, it is suggested that Hydergine can various transmitter systems in the central nervous system.
KeywordsDementia Morphine Serotonin Histamine Choline
Unable to display preview. Download preview PDF.
- Azmitia, E.C.: The serotonin-producing neurons of the midbrain median and dorsal raphe nuclei. In Handbook of Psychopharmacology, Vol. 9, pp. 233–314. New York, Plenum, 1978.Google Scholar
- Biirki, H.R., Asper, H., Ruch, W., and Ziiger, P.E.: Bromocriptine, dihydro-ergotoxine, methysergide, d-LSD, CF 25-397 and 29-712: Effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology 57, 221–237 (1978).Google Scholar
- Carlsson, A.: Age-dependent changes in central dopaminergic and other mono- aminergic systems. Adv. Exp. Med. Bio. 113, 1–13 (1978).Google Scholar
- Carlsson, A., Adolfson, R., Aquilonius, S.M., Gottfries, C.G., Orland, L., Svennerholm, L., and Winblad, B.: Biogenic amines in human brain in normal aging, senile dementia and chronic alcoholism. In Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, pp. 295–304. New York: Raven, 1979.Google Scholar
- Closse, A., Frick, W., Hauser, D., and Sauter, A.: Characterisation of 3H- bromocriptine binding to calf caudate membranes. In Psychopharmacology and Biochemistry of Neurotransmitter Receptors, pp. 463–474. New York: Elsevier/North Holland, 1980.Google Scholar
- Engel, G., Gothert, M., Miiller-Schweinitzer, E., Schlicker, E., Sistonen, L., and Stadler, P.A.: Evidence for common pharmacological properties of [3H]5- hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autorecep- tors in CNS and inhibitor presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn-Schmiedebergs Arch. Pharmacol 324, 116–124 (1983).PubMedCrossRefGoogle Scholar
- Loew, D.M., and Vigouret, J.M.: Neuropharmakologische Charakterisierung von Dihydroergotoxin (Hydergin). In Mutterkornalkaloide heute, pp. 69–79. Stuttgart: Georg Thieme, 1982.Google Scholar
- Markstein, R.: Co-dergocrine has multiple effects on monoaminergic neuro-transmission. Fed. Proc. 42, 496 (1983b).Google Scholar
- McGeer, E.G., and McGeer, P.L.: Neurotransmitter metabolism in the aging brain. In Neurobiology of Aging, pp. 389–403. New York: Raven, 1976.Google Scholar
- Nieuwenhuys, R., Voogd, J., and Van Huijzen, Chr.: The Human Central Nervous System. Berlin: Springer-Verlag, 1978.Google Scholar
- Peroutka, S.J., and Snyder, S.H.: Multiple serotonin receptors: Differential binding of [3H] serotonin, [3H]lysergic acid diethylamide and [3H] spiroperidol. Molec. Pharmacol 16, 687–699 (1979).Google Scholar
- Pradhan, S.N.: Central neurotransmitter and aging. Life Sci. 26, 1643–1656 (1980).Google Scholar
- Schild, H.O.: pA and competitive drug antagonism. Br. J. Pharmacol 4, 277–280 (1949).Google Scholar
- U’Prichard, D.C., Greenberg, D.A., and Snyder, S.H.: Binding characteristics of a radiolabeled agonist and antagonist at central nervous system. Alpha- noradrenergic receptors. Mol. Pharmacol 21, 454–473 (1977).Google Scholar
- Venn, R.D.: Clinical pharmacology of ergot alkaloids in senile cerebral insuf-ficiency. In Ergot Alkaloids and Related Compounds, pp. 533–566. New York: Springer-Verlag, 1978.Google Scholar
- Vigouret, J.M., Jaton, A.L., and Loew, D.: Increased sensitivity after repeated administration of ergot derivatives in rats. Experientia 35, 953 (1979).Google Scholar